Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 44.46% is in line with its 5-year average of 41.02%, near the high end of its 5-year range (4.05%–50.65%).
As of the fiscal period ended Tuesday, March 31, 2026. 8.55% above its 12-month average of 40.96%.
Reported quarterly EBITDA margin; no daily interpolation.
EBITDA MARGIN
44.46%
EBITDA MARGIN AVG TTM
40.96%
EBITDA MARGIN AVG 3Y
41.88%
EBITDA MARGIN AVG 5Y
43.81%
EBITDA MARGIN AVG 10Y
43.49%
EBITDA MARGIN AVG 15Y
39.88%
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+8.55%
CURRENT VS 3Y AVG
+6.17%
CURRENT VS 5Y AVG
+1.49%
CURRENT VS 10Y AVG
+2.22%
CURRENT VS 15Y AVG
+11.48%
CURRENT VS 20Y AVG
N/A
Market Cap
$382.09B
EBITDA Margin
5.21%
TTM Avg
7.15%
3Y Avg
8.47%
5Y Avg
8.86%
Market Cap
$323.72B
EBITDA Margin
45.17%
TTM Avg
41.84%
3Y Avg
33.12%
5Y Avg
31.32%
Market Cap
$634.06B
EBITDA Margin
35.14%
TTM Avg
34.17%
3Y Avg
34.90%
5Y Avg
34.70%
Market Cap
$216.72B
EBITDA Margin
48.42%
TTM Avg
49.59%
3Y Avg
48.46%
5Y Avg
47.82%
Market Cap
$211.18B
EBITDA Margin
24.44%
TTM Avg
24.78%
3Y Avg
25.35%
5Y Avg
27.67%
Market Cap
$179.58B
EBITDA Margin
24.35%
TTM Avg
24.15%
3Y Avg
24.77%
5Y Avg
25.59%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AbbVie Inc. (ABBV) | $458.11B | 44.46% | 40.96% | 41.88% | 43.81% |
| UnitedHealth Group Incorporated (UNH)vs › | $382.09B | 5.21% | 7.15% | 8.47% | 8.86% |
| Merck & Co., Inc. (MRK)vs › | $323.72B | 45.17% | 41.84% | 33.12% | 31.32% |
| Johnson & Johnson (JNJ)vs › | $634.06B | 35.14% | 34.17% | 34.90% | 34.70% |
| AstraZeneca PLC (AZN)vs › | $262.31B | 33.16% | 30.52% | 27.50% | 25.68% |
| Novo Nordisk A/S (NVO)vs › | $216.72B | 48.42% | 49.59% | 48.46% | 47.82% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $211.18B | 24.44% | 24.78% | 25.35% | 27.67% |
| Amgen Inc. (AMGN)vs › | $202.95B | 43.12% | 40.78% | 43.34% | 44.32% |
| Abbott Laboratories (ABT)vs › | $179.58B | 24.35% | 24.15% | 24.77% | 25.59% |
| Gilead Sciences, Inc. (GILD)vs › | $160.55B | 49.12% | 32.26% | 34.27% | 33.90% |
Gross Margin
70.7%
EBITDA Margin
44.5%
Operating Margin
27.6%
Net Margin
5.8%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-03-31 | 44.46% |
| 2025-12-31 | 46.91% |
| 2025-09-30 | 25.15% |
| 2025-06-30 | 45.02% |
| 2025-03-31 | 43.26% |
| 2024-12-31 | 4.05% |
| 2024-09-30 | 40.87% |
| 2024-06-30 | 42.38% |
| 2024-03-31 | 39.58% |
| 2023-12-31 | 36.86% |
| 2023-09-30 | 32.43% |
| 2023-06-30 | 48.85% |
| 2023-03-31 | 40.04% |
| 2022-12-31 | 50.65% |
| 2022-09-30 | 45.96% |
| 2022-06-30 | 36.67% |
| 2022-03-31 | 50.01% |
| 2021-12-31 | 47.38% |
| 2021-09-30 | 44.85% |
| 2021-06-30 | 47.58% |
| 2021-03-31 | 48.56% |
| 2020-12-31 | 41.98% |
| 2020-09-30 | 42.99% |
| 2020-06-30 | 22.13% |
| 2020-03-31 | 48.29% |
| 2019-12-31 | 51.30% |
| 2019-09-30 | 36.80% |
| 2019-06-30 | 47.27% |
| 2019-03-31 | 44.88% |
| 2018-12-31 | -24.07% |
| 2018-09-30 | 43.64% |
| 2018-06-30 | 38.72% |
| 2018-03-31 | 42.20% |
| 2017-12-31 | 27.95% |
| 2017-09-30 | 43.93% |
| 2017-06-30 | 43.79% |
| 2017-03-31 | 42.54% |
| 2016-12-31 | 39.52% |
| 2016-09-30 | 41.43% |
| 2016-06-30 | 41.48% |
| 2016-03-31 | 42.73% |
| 2015-12-31 | 37.09% |
| 2015-09-30 | 35.53% |
| 2015-06-30 | 37.30% |
| 2015-03-31 | 36.61% |
| 2014-12-31 | -4.07% |
| 2014-09-30 | 22.95% |
| 2014-06-30 | 34.86% |
| 2014-03-31 | 33.97% |
| 2013-12-31 | 33.95% |
| 2013-09-30 | 34.46% |
| 2013-06-30 | 36.00% |
| 2013-03-31 | 35.39% |
| 2012-12-31 | 40.91% |
| 2012-09-30 | 40.44% |
| 2012-06-30 | 38.22% |
| 2012-03-31 | 31.08% |
| 2011-12-31 | 35.03% |
| 2011-09-30 | 8.37% |
| 2011-06-30 | 39.34% |
| 2011-03-31 | 29.23% |
